Immunic (NASDAQ:IMUX) Given New $4.00 Price Target at D. Boral Capital

Immunic (NASDAQ:IMUX) had its price target reduced by D. Boral Capital from $8.00 to $4.00 in a research note published on Friday,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

Several other research firms also recently issued reports on IMUX. Brookline Cap M upgraded Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Brookline Capital Acquisition upgraded Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Chardan Capital raised Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Finally, Roth Mkm assumed coverage on shares of Immunic in a research report on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company. Four equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Immunic presently has a consensus rating of “Buy” and an average target price of $6.60.

Immunic Stock Up 4.9%

NASDAQ IMUX opened at $0.91 on Friday. The company has a market cap of $109.76 million, a PE ratio of -1.10 and a beta of 1.58. Immunic has a 52 week low of $0.51 and a 52 week high of $1.39. The firm’s 50-day simple moving average is $0.64 and its two-hundred day simple moving average is $0.76.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05. As a group, equities research analysts anticipate that Immunic will post -0.94 EPS for the current year.

Institutional Trading of Immunic

A number of large investors have recently modified their holdings of the business. Aberdeen Group plc increased its position in shares of Immunic by 678.1% in the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock worth $5,750,000 after purchasing an additional 7,184,457 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in Immunic in the 4th quarter worth approximately $2,337,000. Marshall Wace LLP grew its stake in Immunic by 91.2% in the 4th quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock worth $541,000 after buying an additional 486,468 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Immunic by 414.5% in the 3rd quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock worth $468,000 after buying an additional 427,361 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Immunic during the 3rd quarter valued at $239,000. Institutional investors own 51.82% of the company’s stock.

Key Stories Impacting Immunic

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: Immunic priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds, with $200 million in upfront cash. Immunic Announces Oversubscribed Private Placement
• Positive Sentiment: The company says proceeds will fund completion of Phase 3 ENSURE trials in relapsing MS, start a Phase 3 in primary progressive MS, and finance the transition to a commercial organization — milestones that reduce near-term financing risk if achieved. Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push
• Positive Sentiment: Board and leadership moves: Simona Skerjanec (ex‑Roche neuroscience head) was named interim Chairperson, Thor Nagel (BVF Partners) joined the board, and the company launched a search for a commercially experienced CEO — actions that signal preparation for commercialization. Immunic Announces Oversubscribed Private Placement
• Neutral Sentiment: An analyst note lowered Immunic’s price target (D. Boral Capital cut from $8 to $4) but maintained a buy rating — a reminder that sell‑side sentiment remains mixed and some upside expectations were trimmed. Analyst Price Target Cut
• Negative Sentiment: Significant dilution risk: the financing includes issuance of 229,076,000 pre‑funded warrants priced at $0.873 each for $200M upfront and accompanying warrants that could bring another $200M if exercised — a large potential increase in share count that could pressure the stock long term. Immunic to raise up to $400M to fund late-stage MS trials, commercial push

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.